Company: ATRA
Filing Date: 2025-05-16
Form Type: 8-K
Source: 0001193125-25-121824
Chunk: 0

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-05-16
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01      Other Events.  

On May 14, 2024, the Company entered into an underwriting agreement (the “ Underwriting Agreement”) with TD Securities (USA) LLC, as representative (the “ Representative”) of the underwriters (the “ Underwriters”) named therein, pursuant to which the Company agreed to issue and sell to the Underwriters in an underwritten registered direct offering (the “ Offering”) an aggregate of (i) 834,237 shares (the “ Shares”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock”) and(ii) pre-fundedwarrants (each, a“ Pre-FundedWarrant,” and together, the“ Pre-FundedWarrants”) to purchase up to 1,587,108 shares of Common Stock, at a purchase price of $6.61 per Share and $6.6099 per share underlying thePre-FundedWarrants. The exercise price of eachPre-FundedWarrant is equal to $0.0001 per share, subject to adjustment as provided therein, and thePre-FundedWarrants will be exercisable immediately and have no expiration date.

The Pre-FundedWarrants may be exercised by means of cash or the holder may elect to receive upon such exercise the net number of shares of Common Stock determined according to a formula set forth in thePre-FundedWarrants.

The aggregate gross proceeds to the Company from the Offering are expected to be approximately $16.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Representative is purchasing 834,237 Shares and Pre-FundedWarrants to purchase up to 1,587,108 shares of Common Stock in the Offering at an aggregate purchase price of $16.0 million. The Company intends to use the net proceeds from the Offering to fund its ongoing activities required to achieve the biologics license application (BLA) approval for tab-cel, and for working capital and other general corporate purposes. The Offering was made pursuant to an effective shelf registration statement on FormS-3(FileNo. 333-275256)that was filed with the Securities and Exchange Commission (the “ SEC”) on November 1, 2023 and declared effective by the SEC on November 13, 2023 and prospectus supplement to be filed with the SEC. The Offering is expected to close on May 16, 2025 (the “ Closing Date”).